Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. 2013

Jason Grebely, and Jordan J Feld, and Tanya Applegate, and Gail V Matthews, and Margaret Hellard, and Alana Sherker, and Kathy Petoumenos, and Geng Zang, and Ineke Shaw, and Barbara Yeung, and Jacob George, and Suzy Teutsch, and John M Kaldor, and Vera Cherepanov, and Julie Bruneau, and Naglaa H Shoukry, and Andrew R Lloyd, and Gregory J Dore
The Kirby Institute for Infection and Immunity in Society, University of New South Wales, Sydney, Australia. jgrebely@kirby.unsw.edu.au

Systemic levels of interferon-gamma-inducible protein-10 (IP-10) are predictive of treatment-induced clearance in chronic hepatitis C virus (HCV). In the present study, factors associated with plasma IP-10 levels at the time of acute HCV detection and the association between IP-10 levels and spontaneous clearance were assessed in three cohorts of acute HCV infection. Among 299 individuals, 245 (181 male, 47 human immunodeficiency virus-positive [HIV+]) were HCV RNA+ at acute HCV detection. In adjusted analysis, factors independently associated with IP-10 levels ≥150 pg/mL (median level) included HCV RNA levels >6 log IU/mL, HIV coinfection and non-Aboriginal ethnicity. Among 245 HCV RNA+ at acute HCV detection, 214 were untreated (n = 137) or had persistent infection (infection duration ≥26 weeks) at treatment initiation (n = 77). Spontaneous clearance occurred in 14% (29 of 214). Individuals without spontaneous clearance had significantly higher mean plasma IP-10 levels at the time of acute HCV detection than those with clearance (248 ± 32 versus 142 ± 22 pg/mL, P = 0.008). The proportion of individuals with spontaneous clearance was 0% (0 of 22, P = 0.048) and 16% (27 of 165) and in those with and without plasma IP-10 levels ≥380 pg/mL. In adjusted analyses, favorable IL28B genotype was associated with spontaneous clearance, while higher HCV RNA level was independently associated with lower odds of spontaneous clearance. CONCLUSIONS High IP-10 levels at acute HCV detection were associated with failure to spontaneously clear HCV. Patients with acute HCV and high baseline IP-10 levels, particularly >380 pg/mL, should be considered for early therapeutic intervention, and those with low levels should defer therapy for potential spontaneous clearance. (HEPATOLOGY 2013;).

UI MeSH Term Description Entries
D008297 Male Males
D005260 Female Females
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D016015 Logistic Models Statistical models which describe the relationship between a qualitative dependent variable (that is, one which can take only certain discrete values, such as the presence or absence of a disease) and an independent variable. A common application is in epidemiology for estimating an individual's risk (probability of a disease) as a function of a given risk factor. Logistic Regression,Logit Models,Models, Logistic,Logistic Model,Logistic Regressions,Logit Model,Model, Logistic,Model, Logit,Models, Logit,Regression, Logistic,Regressions, Logistic
D054357 Chemokine CXCL10 A CXC chemokine that is induced by GAMMA-INTERFERON and is chemotactic for MONOCYTES and T-LYMPHOCYTES. It has specificity for the CXCR3 RECEPTOR. CXCL10 Chemokine,CXC Chemokine IP-10,Chemokine (C-X-C Motif) Ligand 10,Cytokine IP-10 Protein,IFN-gamma-Inducible Protein, 10 kDa,Interferon-Inducible Protein 10,Interferon-gamma-Inducible Protein of 10 kDa,Small Inducible Cytokine B10,gammaIP-10 Protein,CXC Chemokine IP 10,CXCL10, Chemokine,Chemokine IP-10, CXC,Chemokine, CXCL10,Cytokine IP 10 Protein,IFN gamma Inducible Protein, 10 kDa,IP-10 Protein, Cytokine,Interferon Inducible Protein 10,Interferon gamma Inducible Protein of 10 kDa,gammaIP 10 Protein
D055815 Young Adult A person between 19 and 24 years of age. Adult, Young,Adults, Young,Young Adults

Related Publications

Jason Grebely, and Jordan J Feld, and Tanya Applegate, and Gail V Matthews, and Margaret Hellard, and Alana Sherker, and Kathy Petoumenos, and Geng Zang, and Ineke Shaw, and Barbara Yeung, and Jacob George, and Suzy Teutsch, and John M Kaldor, and Vera Cherepanov, and Julie Bruneau, and Naglaa H Shoukry, and Andrew R Lloyd, and Gregory J Dore
February 2016, Journal of medical virology,
Jason Grebely, and Jordan J Feld, and Tanya Applegate, and Gail V Matthews, and Margaret Hellard, and Alana Sherker, and Kathy Petoumenos, and Geng Zang, and Ineke Shaw, and Barbara Yeung, and Jacob George, and Suzy Teutsch, and John M Kaldor, and Vera Cherepanov, and Julie Bruneau, and Naglaa H Shoukry, and Andrew R Lloyd, and Gregory J Dore
November 2005, Journal of neuroimmunology,
Jason Grebely, and Jordan J Feld, and Tanya Applegate, and Gail V Matthews, and Margaret Hellard, and Alana Sherker, and Kathy Petoumenos, and Geng Zang, and Ineke Shaw, and Barbara Yeung, and Jacob George, and Suzy Teutsch, and John M Kaldor, and Vera Cherepanov, and Julie Bruneau, and Naglaa H Shoukry, and Andrew R Lloyd, and Gregory J Dore
November 2011, Hepatology (Baltimore, Md.),
Jason Grebely, and Jordan J Feld, and Tanya Applegate, and Gail V Matthews, and Margaret Hellard, and Alana Sherker, and Kathy Petoumenos, and Geng Zang, and Ineke Shaw, and Barbara Yeung, and Jacob George, and Suzy Teutsch, and John M Kaldor, and Vera Cherepanov, and Julie Bruneau, and Naglaa H Shoukry, and Andrew R Lloyd, and Gregory J Dore
January 2015, La Clinica terapeutica,
Jason Grebely, and Jordan J Feld, and Tanya Applegate, and Gail V Matthews, and Margaret Hellard, and Alana Sherker, and Kathy Petoumenos, and Geng Zang, and Ineke Shaw, and Barbara Yeung, and Jacob George, and Suzy Teutsch, and John M Kaldor, and Vera Cherepanov, and Julie Bruneau, and Naglaa H Shoukry, and Andrew R Lloyd, and Gregory J Dore
October 2007, The Journal of infectious diseases,
Jason Grebely, and Jordan J Feld, and Tanya Applegate, and Gail V Matthews, and Margaret Hellard, and Alana Sherker, and Kathy Petoumenos, and Geng Zang, and Ineke Shaw, and Barbara Yeung, and Jacob George, and Suzy Teutsch, and John M Kaldor, and Vera Cherepanov, and Julie Bruneau, and Naglaa H Shoukry, and Andrew R Lloyd, and Gregory J Dore
March 2016, Scandinavian journal of immunology,
Jason Grebely, and Jordan J Feld, and Tanya Applegate, and Gail V Matthews, and Margaret Hellard, and Alana Sherker, and Kathy Petoumenos, and Geng Zang, and Ineke Shaw, and Barbara Yeung, and Jacob George, and Suzy Teutsch, and John M Kaldor, and Vera Cherepanov, and Julie Bruneau, and Naglaa H Shoukry, and Andrew R Lloyd, and Gregory J Dore
July 2008, Microbial cell factories,
Jason Grebely, and Jordan J Feld, and Tanya Applegate, and Gail V Matthews, and Margaret Hellard, and Alana Sherker, and Kathy Petoumenos, and Geng Zang, and Ineke Shaw, and Barbara Yeung, and Jacob George, and Suzy Teutsch, and John M Kaldor, and Vera Cherepanov, and Julie Bruneau, and Naglaa H Shoukry, and Andrew R Lloyd, and Gregory J Dore
April 2012, BMC immunology,
Jason Grebely, and Jordan J Feld, and Tanya Applegate, and Gail V Matthews, and Margaret Hellard, and Alana Sherker, and Kathy Petoumenos, and Geng Zang, and Ineke Shaw, and Barbara Yeung, and Jacob George, and Suzy Teutsch, and John M Kaldor, and Vera Cherepanov, and Julie Bruneau, and Naglaa H Shoukry, and Andrew R Lloyd, and Gregory J Dore
June 2012, The Journal of infection,
Jason Grebely, and Jordan J Feld, and Tanya Applegate, and Gail V Matthews, and Margaret Hellard, and Alana Sherker, and Kathy Petoumenos, and Geng Zang, and Ineke Shaw, and Barbara Yeung, and Jacob George, and Suzy Teutsch, and John M Kaldor, and Vera Cherepanov, and Julie Bruneau, and Naglaa H Shoukry, and Andrew R Lloyd, and Gregory J Dore
January 1997, European journal of immunology,
Copied contents to your clipboard!